PURPOSE: To evaluate the efficacy and toxicity of green tea, prescribed as an alternative complementary (CAM) formulation on hormone refractory prostate cancer (HRPC). METHODS: Patients with HRCP were prescribed green tea extract capsules at a dose level of 250 mg twice daily. Efficacy and toxicity were evaluated during monthly visits. The primary endpoint was prostate-specific antigen (PSA) or measurable disease progression after a minimum of 2 months of therapy. RESULTS: Nineteen patients were enrolled into the study. The treatment was generally well tolerated. Twelve patients reported at least one side effect; only two of these were of moderate or severe grade. Primary toxicity was related to gastrointestinal irritation or caffeine intake. Four patients did not complete the minimum 2 months of therapy because of: intolerance (two patients), physician stoppage (one patient), death from cerebrovascular accident (one patient). Fifteen patients completed at least 2 months of therapy. Nine of these patients had progressive disease within 2 months of starting therapy. Six patients developed progressive disease after additional 1 to 4 months of therapy. CONCLUSION: Green tea, as CAM therapy, was found to have minimal clinical activity against hormone refractory prostate cancer.
PURPOSE: To evaluate the efficacy and toxicity of green tea, prescribed as an alternative complementary (CAM) formulation on hormone refractory prostate cancer (HRPC). METHODS:Patients with HRCP were prescribed green tea extract capsules at a dose level of 250 mg twice daily. Efficacy and toxicity were evaluated during monthly visits. The primary endpoint was prostate-specific antigen (PSA) or measurable disease progression after a minimum of 2 months of therapy. RESULTS: Nineteen patients were enrolled into the study. The treatment was generally well tolerated. Twelve patients reported at least one side effect; only two of these were of moderate or severe grade. Primary toxicity was related to gastrointestinal irritation or caffeine intake. Four patients did not complete the minimum 2 months of therapy because of: intolerance (two patients), physician stoppage (one patient), death from cerebrovascular accident (one patient). Fifteen patients completed at least 2 months of therapy. Nine of these patients had progressive disease within 2 months of starting therapy. Six patients developed progressive disease after additional 1 to 4 months of therapy. CONCLUSION: Green tea, as CAM therapy, was found to have minimal clinical activity against hormone refractory prostate cancer.
Authors: Mike M Nguyen; Frederick R Ahmann; Raymond B Nagle; Chiu-Hsieh Hsu; Joseph A Tangrea; Howard L Parnes; Mitchell H Sokoloff; Matthew B Gretzer; H-H Sherry Chow Journal: Cancer Prev Res (Phila) Date: 2011-11-01
Authors: Addanki P Kumar; Shylesh Bhaskaran; Manonmani Ganapathy; Katherine Crosby; Michael D Davis; Peter Kochunov; John Schoolfield; I-Tien Yeh; Dean A Troyer; Rita Ghosh Journal: Clin Cancer Res Date: 2007-05-01 Impact factor: 12.531
Authors: Huanjie Yang; Dong Kui Sun; Di Chen; Qiuzhi Cindy Cui; Yan Yan Gu; Tao Jiang; Wei Chen; Sheng Biao Wan; Q Ping Dou Journal: Cancer Lett Date: 2009-12-03 Impact factor: 8.679